A case report describing a suspected rivaroxaban hypersensitivity reaction in a surgical patient

Abstract

We believe this to be the first published case of hypersensitivity associated with rivaroxaban. More research is needed to determine this association. At the same time, given the growing range and increasing use of anticoagulants, particular vigilance is required regarding potential side effects so that these may be managed quickly and effectively in the early stages.

Bullous pemphigoid‐like skin rash associated with Rivaroxaban use in a very elderly patient with multimorbidity and chronic kidney disease: A case report

“…After reviewing the published case reports on skin reactions associated with rivaroxaban, a decision was taken to suspend rivaroxaban on 17 July 2019. Subsequently, the patient and his family did not want any further anticoagulation medication in view of the complications with rivaroxaban and his history of recurrent falls with physical injuries.…”

“…rivaroxaban is an example of a DOAC, and apart from bleeding, less common side effects include hepatobiliary toxicity, hair loss, skin reactions, and hypersensitivity reactions including anaphylaxis . There have been a number of reports of rash occurring with rivaroxaban use . A bullous‐like skin rash has been described in some of these studies, which may be mistaken for the condition of bullous pemphigoid.…”

“…2 There have been a number of reports of rash occurring with rivaroxaban use. [3][4][5][6] A bullous-like skin rash has been described in some of these studies, 7 which may be mistaken for the condition of bullous pemphigoid. Manufacturers warn of the following dermatologic adverse reactions in the package insert of wound secretions (3%), pruritus (2%), and skin blister (1%).…”

A case of rivaroxaban‐induced subacute lupus erythematosus

“…Cutaneous adverse drug reactions (CADRs) to IM Glucantime â have been reported in less than 1% of the patients. [1][2][3][4] They occur more frequently after IL administration, being described in about 3% of over 1000 reported cases. [2][3][4][5][6][7][8][9] These comprise both type-I and type-IV allergic reactions.…”

“…Previous reports of dermatological side-effects related to rivoraxaban include acute generalized exanthematous pustulosis (AGEP) and drug reaction with eosinophilia and systemic symptoms (DRESS syndrome). 1,2 Hypersensitivity reactions were also observed. To our knowledge, there have been no previous reports of rivoraxaban causing cutaneous lupus, photosensitivity or phototoxicity.…”